SCHEMBL5160113

SCHEMBL5160113

Fc1cccc([C@H](CCCl)Oc2ccc(C(F)(F)F)cc2)c1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 5/20 0.71
SLC6A4 P31645 5/20 0.56
SLC6A2 P23975 4/20 0.56
SLC6A3 Q01959 4/20 0.56
KCNK2 O95069 2/20 0.56
KCNH2 Q12809 2/20 0.56
CACNA1C Q13936 2/20 0.56
MEN1 O00255 4/20 0.52
KMT2A Q03164 4/20 0.52
LMNA P02545 4/20 0.52
HRH3 Q9Y5N1 2/20 0.52
NPC1 O15118 2/20 0.52
CYP2D6 P10635 2/20 0.52
CYP2C19 P33261 2/20 0.52
MTOR P42345 2/20 0.52
RAB9A P51151 2/20 0.52
CYP3A4 P08684 2/20 0.52
HTR2C P28335 2/20 0.52
KDM4E B2RXH2 1/20 0.52
TP53 P04637 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5160122 1.00 SLC7A5 (0.71) SLC7A5SLC6A4SLC6A2SLC6A3KCNK2
SCHEMBL2690834 0.86 SLC6A4 (0.74) SLC7A5SLC6A4SLC6A2SLC6A3KCNK2
SCHEMBL5574872 0.86 SLC6A4 (0.74) SLC7A5SLC6A4SLC6A2SLC6A3KCNK2
SCHEMBL5577138 0.86 SLC6A4 (0.74) SLC7A5SLC6A4SLC6A2SLC6A3KCNK2
SCHEMBL6005053 0.85 SLC6A4 (0.56) SLC7A5SLC6A4SLC6A2SLC6A3KCNK2
SCHEMBL5158683 0.84 SLC6A4 (0.58) SLC7A5SLC6A4SLC6A2SLC6A3KCNH2
SCHEMBL5162687 0.83 SLC6A4 (0.77) SLC7A5SLC6A4SLC6A2SLC6A3KCNK2
SCHEMBL17284126 0.83 SLC7A5 (1.00) SLC7A5SLC6A4SLC6A2SLC6A3KCNK2
SCHEMBL5162694 0.83 SLC6A4 (0.77) SLC7A5SLC6A4SLC6A2SLC6A3KCNK2
SCHEMBL6013735 0.82 SLC6A4 (0.68) SLC7A5SLC6A4SLC6A2SLC6A3KCNK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1790337-A2 Methods and compounds for treating depression and other disorders NPS PHARMACEUTICALS, INC. (US) 2007-05-30 EP disclosed
EP-1096926-B1 METHODS AND COMPOUNDS FOR TREATING DEPRESSION NPS PHARMA INC (US) 2007-02-28 EP disclosed
US-20040039014-A1 Methods and compounds for treating depression and other disorders NPS PHARMACEUTICALS, INC. 2004-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040039014-A1 Methods and compounds for treating depression and other disorders GRIN1, GRIN2C, GRIN3B SLC7A5 294/4885SLC6A4 24/4885SLC6A2 89/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.